Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Scroll down and select country
MEBO TMAU TESTING CURRENTLY SUSPENDED INDEFINITELY

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO Private Facebook Group
to join : go to
or contact
Ubiome Gut EXPLORER
10% OFF

Update : discount is suspended
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

London TMAU meeting with Prof Liz Shephard
19th Oct 11am - 1pm
St Mary's Hospital
Praed St, Paddington
London W2 1NY
click to read more

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Friday, August 16, 2019

Polish study : Does TMA not TMAO cause CVD ?

A Polish lab this week published a paper saying in the study they did in rats, that Trimethylamine seemed to be related with smooth muscle damage in rats, rather than TMA-oxide.

This is obviously of great interest to the TMAU community because :
1. It would mean TMA would be associated with heart disease.
2. It might mean more anti-TMA therapies i nthe future (if not already on the way).

TMA-oxide and Heart Disease
In 2011, Cleveland Clinic Heartlab first suggested the hypothesis ... TMA-oxide is a BIOMARKER and CAUSE of damage that leads to HEART DISEASE etc.
This small Polish study suggests in rats it's TMA that is the BIOMARKER and perhaps a CAUSE, rather than TMAO.

What to think ?
This is the way research goes. One lab says one thing and another says another.
e.g. The way studies say butter is good (or bad ) for you.
Then over time a consensus is decided (e.g. climate change or not ?).

So for now the 'TMA - CVD' theory could be a blip or the correct theory, or neither ??

Polish lab
It's good to see a Polish lab interested in TMA and TMA-oxide.

Leaky Gut 
Also interesting to see LEAKY GUT get a mention in the study.
They say older rats more prone to 'leaky gut', leading to more TMA absorption (??).   

Poland study Aug 2019
TMA but not TMAO increases with age in rat plasma and affects smooth muscle cells viability

Quote ...
In vitro, TMA at concentration of 500 µmol/L (2-fold higher than in portal blood) decreased hVSMCs viability. In contrast, TMAO at 1000-fold higher concentration than physiological one, had no effect on hVSMCs viability. In conclusion, older rats show higher plasma level of TMA due to a “leaky gut”. TMA but not TMAO affects hVSMCs viability. We propose that TMA but not TMAO may be a marker and mediator of cardiovascular risk.     

Upcoming Anti-TMA pill made by Procter and Gamble 
P&G in association with Cleveland Heartlab will be producing an 'over-the counter' TMA-inhibiting supplement in the future.
It is unknown when it will market.
Speculation to the supplement reaching market could be from 2020 to maybe 2023 or later.
It's top secret and nothing is told to MEBO.

get New Posts by EMAIL : Enter your email address :



A EURORDIS and NORD Member Organization

1 comments:

Unknown said...

I cant wait to have that pill here in winnipeg canada. I hope it is over the counter and no need for prescription of a doctor. If anyone is updated about this pikl please let me know i want to know more about thi pill. And if it can really make my body odor gone for good. And do i have to take it for a lifetime?

Aug 16, 2019, 8:46:00 PM
Post a Comment